原文出处：Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
原标题：心衰新药！拜耳/默沙东首创sGC刺激剂vericiguat显著降低心衰住院或心血管死亡复合风险！
本文来源自生物谷，更多资讯请下载生物谷APP(
http://www.bioon.com/m/)
